OGOMEGBUNAM OGBONNA: Open Payments
NPI 1134654528 · FT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,518 in 73 payments from 10 companies in 2025. Trend: 2023 $2,499 · 2024 $1,597 · 2025 $1,518
Food & beverage: $1,518
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $470 |
| E.R. Squibb & Sons, L.L.C. | 13 | $336 |
| Teva Pharmaceuticals USA, Inc. | 13 | $220 |
| Neurocrine BioSciences, Inc. | 6 | $175 |
| Janssen Pharmaceuticals, Inc | 12 | $158 |
| Vanda Pharmaceuticals Inc. | 4 | $79 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $16 |
Products named: CAPLYTA, COBENFY, AUSTEDO XR, INGREZZA, INVEGA SUSTENNA, FANAPT, UZEDY, Auvelity.
Industry payments across TX — which companies pay providers there.
